|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2900 Ames Crossing Road |
Address2 |
|
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
|
5. Senate ID# 400339576-12
|
||||||||
|
6. House ID# 403630000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: David Root |
Date | 10/19/2022 1:05:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Education on the value of biosimilars; H.R. 19/S. 2164: "Lower Cost, More Cures Act," provisions on drug prices and Part D cost-sharing and Part D reform. H.R. 5376/P.L. 117-169: "Build Back Better Act"/"Inflation Reduction Act," provisions relating to insulin cost-sharing; repeal of the rebate rule. S. 3700/H.R. 6833: "Affordable Insulin Now Act," provisions related to cost-sharing for insulin in Medicare and private plans. Draft versions of the "INSULIN Act," provisions on cost-sharing, utilization management and rebates for insulin. S. 4293: "The Pharmacy Benefit Manager Transparency Act of 2022," provisions on the FTC regulation of PBMs. S. 1388: "Prescription Pricing for the People Act of 2021," provisions related to an FTC study of PBMs; provisions related to restrictions on spread pricing in the commercial market for PBMs. H.R. 7666: "The Restoring Hope for Mental Health and Well-Being Act of 2022," Title VI, Sec. 602, Oversight of Pharmacy Benefit Manager Services.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees." Outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed and Final Rules, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program. H.R. 19/S. 2164: "Lower Cost, More Cures Act," provisions on drug prices and Part D cost-sharing and Part D reform. H.R. 5376/P.L. 117-169: "Inflation Reduction Act"/"Build Back Better Act," provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule. S. 3700/H.R. 6833: "Affordable Insulin Now Act," provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans. Draft versions of the "INSULIN Act," provisions on cost-sharing, utilization management and rebates for insulin. H.R. 8487: "Seniors Timely Access to Care Act," general education on prior authorization.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |